
- BioPharm International's BP Elements, June 2023
- Volume 2
- Issue 6
ProBioGen Launches Lentivirus Packaging Cell Line
ProBioGen’s Lenti.RiGHT is a lentivirus production platform for use in gene transfer applications.
ProBioGen, a Berlin-based company specializing in the development and manufacture of APIs, announced its new lentivirus packaging cell line on May 17, 2023. Lenti.RiGHT is a lentivirus production platform based on human embryonic kidney 293 packaging cells.
According to a company press release, the new line is capable of producing lentiviral particles with titers between 107 and 108 transducing units per mL. It includes stable integration of gag-pol, rev, and vesicular stomatitis virus-G proteins.
"With our Lenti.RiGHT platform we have developed a new standard for efficient large-scale lentivirus production and CAR–T [chimeric antigen receptor T cell] manufacturing,” said Volker Sandig, chief scientific officer, ProBioGen, in the release. “It enables an inducible, scalable, and efficient production of high-titer lentiviral particles for gene transfer applications.”
Source:
Articles in this issue
over 2 years ago
Difficulties in Expanding CAR-T Cell Therapy into Solid Tumorsover 2 years ago
Sartorius and Waters Expand Analytics Collaborationover 2 years ago
Domino Data Lab Expands AI Platformover 2 years ago
Lonza Acquires Synaffix in ADC Dealover 2 years ago
TriLink Biotechnologies Introduces CleanCap M6 Analogover 2 years ago
New QSAR Model for Predicting Blood Brain Barrier PermeabilityNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.